source
- FDA expands Anktiva use for BCG-unresponsive high-grade papillary bladder cancerThe U.S. Food and Drug Administration has broadened the approved use of Anktiva, a therapy given with Bacillus Calmette-Guérin, to treat adults with high-grade papillary-only bladder cancer that ha…
- Gilead invests up to $1.87 B in Vir Biotechnology for three T-cell engagersGilead Sciences announced a licensing agreement with Vir Biotechnology that includes an equity investment and potential milestone payments totalling up to $1.87 billion. The upfront component is $…